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Figure 1. lmnnmohietochemieal double staining of an atheredomy
apeeimm froma revraoite human femoral artery retrieved 6 months
after the laidal angioplasry
. The and rattler stains; labels cells
positive for ptalAYattng cell nuclear antigen, suggesting a very high
paliferadaa activity in this specimen . Additional staining with the
mastic scrim-specific antibody HHF-35 . indicated by
beau. eyto-
peaak staining,
moutons
that moat of the proliferating cells arc in
fact
smooth
muscle Cons. tart shows proliferating cell nuclear
antigen-positive smooth muscle calls at a higher magnification .
of the agent deposited in the arterial wall. The latter depends
principally on how the agent is delivered to the artery . Most
catheter devices developed for local delivery have been
Figure 2. Schematic of several catheter systems used for inum as-
ev r drug delivery. M Doublahmloon catheter used to inlne dug
mission into an antonial compartment isolated by two balloons . II,
Paeaaa balloon catheter. Agents are Itdeeted into the wascular wall
tlveeah total inclinations in the siuglalunen balloon catheter . C.
Mkreporoia baleen. A panes balloon is covered by a permeable
polycarbmmae membrane (pore size 0.8 Non) to reduce jet-induced
igjtay. D, Channel balloon. Drug are inflated through small parfo-
mind channels its" an the :canes of an agioplosty balloo .
Pressures fee balloon Inflation and drug infusion thus can be
sepntad. F, Stem in a balloon . A different system far the low
patoe inawlon of drags by ate of a expandable atom within the
heinous ap~~ the balloon agulntt the arterial wall . P. Bydregel
catheter. A hydsaphife polymer eating acts as a dugabashieg
sponge. Agate au tsenrfmred ro the areral wall daing balloon
inflation.
a
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designed to accomplish infusion of short-lived aqueous
so-
lutions into the vessel wall. Alternatively . polymers de.
signed as miceuparticles or stoats have been modified to
provide timed, including longer-lived, release of the them-
penile agents .
Devices for Intravascular Drug Delivery
DonMtibagsou catheter. The first device used for the
localized delivery of drugs or genes was the double-balloon
catheter (7-9) (Fig. 2A) . By inflating the two balloons, a
scaled Compartment is created in which the solubilized
therapeutic want can be introduced after blood has been
evacuated from the compartment. The injected mixture
reaches the arterial wall by diffusion or as a result of applied
hydrostatic pressure. It has been recently shown that infu-
sion pressures of 150 mm Hg (0.2 arm) are both nontraumatie
and sufficient forthe uptake of deoxysibese nuclricocld )NA)
plasmids into the arterial wall ; pressures X500 min Hg typically
create additional injury (10) . The double-balloon catheter
may be particularly well sealed for nonangiopesty applica-
tions in which the endothelium is the delivery target .
Clearly, one of the potential advantages not shared by
alternative delivery devices is that the double-balloon cath-
eter provides a design option for evacuation, in addition to
instillation, of the compartment isolated between two in-
flated balloons. This issue is particularly relevant for agents
such as vital vectors in which systemic circulation may be
undesirable .
However, the clinical use of the double-balloon catheter
is limited by certain practical problems, such as leakage of
the solution through side branches and relatively long incu-
bation times of 15 to 30 min . Foully, the inflation pressure
required to accomplish a satisfactory seal by the two bal-
loons of the delivery compartment can lead to additional
vessel injury proximal and distal to the target site . Use of
ultracompliant latex in lieu of conventional polyethylene
balloon material may help to prevent this occurrence .
Form balmw off. The porous balloon (Fig. 28)
was first used for intramusndar drug delivery by Wolimky
and Thong (11) and has recently been used for intravasmdar
gone therapy by several investigators (12,13) . Drug orDNA
solutions can be delivered into the balloon under pressure
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eatheterleads to high local tissue concentrauom :of the drug .
which. however, decrease rapidly within a few hours (26).
Show. Scents have been proposed as useful carriers for
sustained local drug delivery of antithrombutic or amiprotif .
crative drugs, or both, and genes. Several approaches have
heap investigated to achieve continuous drug release from a
stets. First. metallic steers have been seeded with geneli-
cally modeled endothelial cells to date agents such as tissue
plasminogen activator (t-PA) (27). Second. stets can be
coated directly with dregs or with drug-eliding biodegrad-
able polymers. Third . stems can be maoulietoed completely
o..f. ~d.1rug-eluting biodcgadable polyntas (25.29) . Several biode-
Bradnble polymers, such as potylecdde, polyglycotide, poly-
nethoster, polycepmMctone. pdyhydroaybutyrate and poly-
ethylene oxiddpolybutylene terephthalate. have been
investigated for this purpose (28,29) . Preliminary experience
with these materials may favor stems made of potytactide
because ibis material canbe used to release drugs and causes
only a mild tissue reaction (30), in contrast to the other
materials that have been shown to evoke an extensive
foreign body reaction
(31).
Fibrin has also been used to coat
metallic stents and has been reported to reduce the incidence
of stet occlusion withoa causing a significant inflammatory
response (32). Finally, removable nitinal stems, developed
with a drugShtting polyurethane coating (331, represent a
new approach in which therapeutic agents might be deliv-
ered for a definite period, after which the device
. and any
stent-related liabilities, could
be removed .
Potential Therapeutic Agents for Local Drug
Delivery
CowerWrl drugs. In the past few years a number of
d''erent, An still paeliminary, studies have investigated
the efech of variou agents for local drug delivery
. Because
of its known aarithrcmbotir and antiproliferstive properties.
heparin was aim of the first drugs tested . Delivered through
a porous balloon, heparin has been demonstrated to persist
in the media of the arterial wall for up to 48 h (11). A
hydruguFcaated balloon has also been shown to achieve
elficiam delivery of heparin into the vaucuhr wall in vitro
(34) . By use of a Dacron graft shunt model, local heparin
delivered in vivo from a hydrogel balloon was fouad to
inhibit plaleltdepeodeat
thranhosis (35) . However. exper-
imental studies Involving local heparin delivery in a rabbit
model of atherosckrosis failed to show any effect on restett-
oils when hepatic was delivered through a porous balloon
(36)
. Heparin-coated scents likewise failed to reduce intimal
prolileaation in several experimental studies (37,38), but, a
preliminary study, testing local delivery of low molecular
weight heparin through a porous balloon showed a favorable
effect of this heparin preparation on thrombus and utrnimi-
mal formation in an atherosclerotic rabbit model (39). Local
delivery of angiopeptin (40)
.
0tiol protease inhibitors (41),
Bole hicine
(42). doxondlicin (16) or methotrexate through a
porous balloon (43) or a scent (37) all filed to inhibit the
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development or intimat hyperplesia . One possible explana-
lion for the failure of these latter experimental studies may
be the multifactorial nature of restenosis that resists any
treatment strategy designed to address only a single mecha-
nism
. It is possible to consider combination chemotherapy,
that is, delivery of several agents that synergistically act to
retard vessel narrowing through multiple mechanisms .
Agents that block protein synthesis . extracellular matrix
production and thrombus formation could thus be applied in
combination .
Because drug solutions can be cleared rapidly from the
arterial wail by both convection and diffusion, another
potential explanation for the failure of locally applied single-
dose drug delivery to thus far achieve dramatic benefit is that
the residence time of the agents used has been insufficient
.
Mare than 9055 of deposited colchicine . for example. is
cleared within a few hours after local intraluminal delivery
from a porous balloon (42) . In contrast . sustained release of
heparin from a periadventitial depot effectively reduced
neointimal proliferation and local thrombus formation in the
balloon-injured rat carotid artery made] (44-46). Heparin in
these cases was administered in an ethylene-vinyl acetate
copolymer matrix (44) or a polyvinyl alcohol gel surrounded
by a Silastic shell (45,46). Similarly, dexamethasone has
been shown to inhibit neointimal proliferation in the balloon-
injured rat carotid artery model when delivered locally from
a silicone polymer implanted in the adventitia (47) . Although
surgical placement of drageluting matrices is impractical for
most clinical applications, one approach to minimize drug
washout try use of percutaneous, transarterial delivery is the
use of nondittitnble. drug-eluting auicroparlicles
. Similar to
biodegradable sterns, these nticroparticks can be manufac-
lured from a variety of synthetic polymers (e.g.. polylactide)
or natural substances such as proteins or polysaccharides
.
variables such as total dose of drug and kinetics of release
ran he strategically manipulated . Again . biocompatibilitY of
the material or materials used is a major issue to be resolved
because of the potential for a foreign body reaction precip-
itated by the polymer. Microparticles can be injected of l-
ciently into the arterial wall through a porous balloon (48) or
a balloon over asrenr (20) and are retained in the arterial wall
as well as in the periadventitial tissue for at least 2 weeks.
However, although biodegradable micropartieles that re-
lease cotchiciae have been shown to inhibit smooth muscle
cell proliferation in vitro (49).
no such effect could be
demonstrated in vivo (50).
In addition to inhibiting restero-
sis. local delivery of therapeutic agents might also prove
useful in other, more acute situations . In a preliminary
study, Mitchel et al . (51) reported that acute thrombotic
occlusions of coronary arteries after angioplasty could
be
successfully reopened by balloon dilation with urokinase-
coated hydrogel balloons
. This approach may well represent
an attractive alternative for patients with contraindications
to systemic thtmnbolysis or
patients with systemic therapy
that failed to lyse occlusive thrombus .
6
-
3
~
1
1
1
1
	
a
g
	
8
	
i
°
	
=
a
s
~
~V
j
j
q
4
!
I
j
I
l
l
I
h
1
I
1
I
i
h
1
H
I
I
I
!
L
i
d
u
i
r
e
v
K
	
.
8
	
VI
A
i
l
l
	
$
!
t
9
p
	
-
g
	
p
	
~
3
 
~
	
e
H
I
M
T
M
"
I
JAM VoL 23. No. 3
April IW1:1731-l4
lovirns, Runs sarcoma virus or simian virus 40 promoter
(10
.13,22) . Although the use of these promoters has been
associated with varying levels of gene expression, none are
tissue specific . hsur-specific endogenous promoters (e .g . .
an actin promoter if
the target cells are smooth muscle cells)
may further refine arterial gene tmosfen by allowing one to
resttict gene expcss(on to certain cell
types within the
arterial segment at the site of transfecxion .
The third component affecting tran*ction efficiency is
The trammtaial delivery device. The first device used for
iMravaseular gene delivery of marker genes such as beta-
gelecwsidase and luciferase was the double-balloon catheter
(9,64)
. In our experience, transkctinas performed with
Ieclismae plasmids
. mixed with liposotttes and applied
through
a double-balloon system in a rabbit model resulted
in low 6egneney and low levels of gene expression (64). In
contrast, arterial gene transfer with luciferase DNA only (no
8posomes. viruses or other vectors) through a hydrogel
balloon was consistently successlhl (22). and mean lu-
cdaase expression was increased by more Yore two orders
of magniNde compared with previous experiments using the
double-balloon system . Gene expression was achieved with
infstion times as short as 1 min
. Auturadiographic studies
demonstrated that DNA was delivered to the entire media,
with the highest concentration in the aubimimal cell layers
(Pig
. SA), Additional transfeetiaas with the marker gene for
nocleonapeelfic belallilacmsidase (Pig
. 58) showed that
nanhction was restricted to
only a few cells, predomi
nastiy located in
the subintimal layer, indicating that the
higher DNA concentration and mechanical faces achieved
directly at the haloon-artery iderihce optimize cellular
uptake ofDNA. Others (12,13) have used purcus balloons to
peefam lam transfer with retrovleuses or planmid DNA .
Cutretltly. ail of these devices are also being evaluated for
adenoviml gene wanner 172) .
hidhect one transfer co st(nnes an alternative, albeit
sews wmhersoma, to direct modes of
on
transfer previ-
allnly described . Cells targeted for gene transfer are removed
from the potential recipient and are transtected with the
temMbisaM gene . after which the successfully transfected
units am selected far relmpla mom at a speeme recipient
site in vivo. Both andado ial cells and smooth muscle cells
Weban reimplanted according to this paradigm at previ-
enuly denuded sites by at of a double-balloon catheter
(81,82?. Similarly. stems seeded with genetically erglneered
M dusts ial cells have been used to achieve tranavescular
Introduction (27).
AMieame ullpauchetidm . Antisense oligonuckotides
are short segments of synthetic DNA that are in general
chemically
modified
to resist enzymatic degradation by
intracellular or exnaeellular nucleases. Alter cellular up-
take, antiseese ofgonucleotides can bind in a relatively
specific manner to a complementary messenger ribonucleic
acid (mRNA). The action of RNase H on the resulting
DNAIRNA hybrid readers this segment of mRNA unavail-
able for translation. The advantage of aMisenne oligonude-
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otides is that they can be specifically targeted against
mRNAs for those proteins essential for cell proliferation.
Some of these proteins are strategically bested near the final
common pathway into which multiple . paetalty redundant
signal transduction pathways (including growths factors and
their receptors) converge
. Antisease oligoucleutides tar-
geted against a variety of mRNAs, including proliferating
cell nuclear antigen (83), aonmusde myosin (B4) and the
proto-oncogenes c-myb (84) and raryc (85.86), have been
shown to partially inhibit smooth muscle cell proliferation in
vitro
. This effect has been shown so persist for several days
in cultured cells exposed to aatiseuse far only 2 It. In
experimental animal models
. antisense digonucleotides ad-
ministered in vivo have been found to reduce neointimat
formation after denudation of art carotid (87,88) or porcine
coronary arteries (T
.alewshi A, personal communication, De
cember 1993)
. Simpns et a)-
(87),
for example, applied c-Mb
aatisense oligonucleotides in combination with a pluronic gel
to the surgically exposed adventiti of she art carotid artery .
The polymer used in this case has the physical property of
being liquid at 4°C but then forts a highly viscous gel at
body temperature. Morishita et at. (88) mixed antisense
oligonucleotides, prepared against cyclin cdc2 and prolifer-
sting-cell nuclear antigen, with inactivated viral particles,
tipoaomes and a nuclear protein and then injected the
solution into the hnmenof a ligated rat carotid artery . Studies
designed to lest The erect of a variety of antisense oligonu-
clcotides administered percutaneously to inhibit arterial nar-
rowingare currently ongoing o a number of laboratories
. In
all cases, selecting of the particular antisense strategy
is
based in part on idontilyltg a targeted mRNA present in low
abundance and a eoneaponding protein with a short half-life,
Issues that remain to be addressed if this strategy is to be
successfully applied clinically as therapy include the amount
of oligoaudeotide that can be delivered, the stability of the
oligonucleoudes in the vessel wad and, perharhmost crital
inthe ea se of restenosis,timing
of
administration compared
with mechanical intervention.
Systemic Adminialrntbn of Inactive Agents
Followed by Localized Activation
Photodyamie therapy constitutes a form of local therapy
in which the activity of light-excitable photosensitizera is
exploited to produce Injury of targeted cells. Photosensitlz.
em are relatively nontoxic substances unless they are acti-
vated by the appropriate wavelength of light . Hematopor
phyrin derivatives, activated by red light with a wavelength
of 635 am, have been used for the treatment of neoplastic
disorders (89). These substances accumulate in the proli er
ating tissues, such as tumors, and have also been ahowrr to
he present in higher concentrations (n atherosclerotic plat ue
than in normal arteries after systemic administration (SO) .
Cultured smooth muscle cells from athetueclerotic plagtes
also show a higher sensitivity to hematoporphytins than
1240
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::M-
S. A, Automdiogmm of a mbbh carotid artery
performed
ngioplasty with a hydrogen balloon cooled with "S-
radklebeled piasmld DNA . The highest density of silver grape
indicating the presence oftediolabeled DNA Is Panad In
the
htyers of
the arterial wall bordering the lumen . d, Histologic section of ∎
rabbit carotid artery 3 days after tmnsfcetiaa with the
corker
gene
for nuclear-epeclftc beta-galacsosidase . A hydra el balloon was
coated with Mpg plasmid DNA and Inflated in The artery for S min
at 9-arm pressure. Three subimimd
calls
MUMS the gem for
nmlear•apeeIftc bear-galaesosidase can beientified by the dark-
him omlear staining (arrow). Additional homunoemiolao with anti-
bodies against muscle acdo (HHF-33) shows the prCdnmimoce of
amotth muscle cells in the arterial wall . Hematuxylin-coin.
smooth muscle cells from normal arteries (91) . Catheter-
based light delivery systems are now available for intravas-
collar photodynamic therapy (92) . Photodynamie therapy
involving administration of a hem atoporphyrin derivative,
followed by flash-lamp irradiation delivered through a quartz
fiber catheter with a didbsing tip was shown to inhibit
necinlimal formation in a rabbit model (93). This effect,
achieved when the treatment was administered immediately
or delayed for I week after balloon injury . was associated
with extensive medial smooth muscle cell necrosis, indicat-
ing that medial smooth muscle cells also take up photosen-
sitizer directly after arterial injury . Treatment at later time
points was shown to target mom selectively the neointimal
tissue . It remains to be shown whether medial smooth
JACC
Val.
23, Nn 5
Ape 1991:1276-44
Flgare 6 Tq, Uauastsd rat carotid smty 3 weeks alter bdkoa
injury demonstrating
a
think aeoislina OW)
. lilies, Section era
rat cmadd artery 3 weeks after beflom &cud lkat foliwed by
radiation with low dates dWasvkdet light goomated atom a diode
laser
in
the absence ofany photansiGum . The presence of only
few cell euclel in the medic (M) Indicates smooth marcle ad
necrosis
. The artery dams not show any rm®timd proliferation .
IBM - Internal shark memhmm,
muscle cell necrosis predisposes to vascular complications
such m aneuryemal dilation or perforation, but clinical
experience with laser balloon angioplasty (94) suggests this
is unlikely to be a frequent concern . A second issue for
which there is limited data (9S) is the possibility that proteins
released from necrotic cells might represent potent mitagens
capable of Initiating a secondary wave of cell proliferation .
The clinical use of hemelopoephydne in the past has been
limited by a cutaneous photosensitivity that can lest for
several weeks. To reduce the systemic photdoxicity, lower
doses of new hematoporphysin derivatives have been admin-
istered locally through a porous balloon (96). Likewise
.
chlorodominum-sulfoaated phthalocyanin inhibited neolmti
mal formation in rats after balloon injury and also produced
necrosis of the media (97) . This substance is nonphototosic
and is also preferentially taken up by neointimal cells (9d).
Pscealen represents an alternative photosensitizer currently
under investigation as an agent to be administered in con-
JACC Vd. a . Na.
s
Ap 71954:1214-44
junction with ultraviolet irradiation . This photosensitizes .
routinely used for the treatment of dermatolngic disorders .
has limited systemic toxicity . A single exposure to psoralen
ultraviolet A (PUVA) radiation was shown to result in
complete stasis of cell proliferation over a 211-day period
without cell necrosis (99) . Fatally, preliminary studies from
our laboratory have suggested that very low doses of ultra-
violet radiation generated from a diode laser and delivered
locally to an isolated segment of rat carotid artery in vivo can
inhibit smooth muscle cell proliferation and cause medial
necrosis even when used alone, with no phoeoacdve agent
(fig . 6) (100).
Syetesnic Admiofstrailon of Agents With a
Specific Affinity to Proliferating Smooth
Muscle Cells
Proliferating smooth muscle cells, compared with quies-
cent cells, often express higher numbers of cell surface
receptors for a variety of growth factors
. Differential expres-
sion of growth factor receptors may provide the opportunity
to use cytotmdc agents that specifically target proliferating
smooth muscle cells. Targeted delivery of cytotoxiae to
specific cell surface receptors may be accomplished with
recombinant Ibsion proteins . These chimeric agents combine
a potent toxic with peptide ligands to cell surface receptors.
After receptor binding and internalization
of the prtltein.
action of the toxin results he cell death
. For the receptor
rargetirtg component, several growth factors have been used,
Including misinforming graMh factor alpha (10l) . epidermal
growth actor (102). basic dbroblast growth factor (103 .104)
and oteleukio-2 (1031
. Toxins that have been used to
complete 0u hybrid include a modified Pseadomonas exo-
toxin (101
.103), diphtheria toxin (102) and saporin (104), a
toxin directed at ribosomal RNA. In cell culture, these
fusion toxins preferentially kill rapidly proliferating smooth
m scle colts, compared with quiescent cells (101,104)
. A
recombinant CYtomxmt specific for the epidermal growth
factor receptor was also shown to
prevent smooth muscle
cell outgrowth from human atheroscle otic plaque in culture
(102). We (106) and others (104) have used the balloon-
injured rat carotid artery model to study the effects of
recombinant fusion proteins on necintimal formation in vivo .
Systemic intravenous delivery of afusion protein was shown
by Casace0u et al
. (104) and more recently by Picketing et al .
(106) to
inhibit iatimal proliferation but was also associated
with systemic toxicity, manifested principally as weight loss .
Such systemic toxicity is mot altogether unanticipated be-
cause of the fact that growth factor receptors are not
exclusively expressed by proliferating smooth muscle cells
but are also present an cells from other organs such as the
liver and gut . Previous nonvaacular use of these fusion
Dancing suggests that the doses used in the rat would be
umiteely to exhibit similar toxicity in humans
. Nevertheless,
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even in the case of a systemically administered agent de-
signed to be activated locally, there may well be a role for
local delivery
. Preliminary experience in our laboratory has
demonstrated that local administration of the fusion protein
to a segment of balloon-injured rat carotid artery resulted in
markedly reduced netJmtimal formation with clearly reduced
systemic side effects (till) . Thus, although this treatment
strategy was originally designed as targeted systemic ther-
apy . its future clinical use might well be local delivery
through an intravascular delivery system . Several questions,
however, must first be resolved. These include foremost the
optimal ti,ae point at which to apply the toxin . Application
immediately after angioplasty might be most practical, but
uncertainty with regard to the time interval between balloon
injury and the onset of increased expression of receptors in
proliferating cells remains a concern . Second, the long-term
consequences of intimal and medial cell necrosis, or both, as
discussed previously, are unclear .
Conclusions
Local drug delivery represents a potentially valuable
adjunct to the treatment of restenosis and other vascular
diseases . Several prototype devices have been developed
and tested in vivo. Further modifications are expected to
achieve more
efficient
delivery without concomitant tissue
damage
. Additional studies will be required to demonstrate
the logical but yet unproved concept that the efficacy and
safety of pharumcalogic substances conventionally adminis-
tered systemically is superior when delivered locally and to
clarify the efficacy and safety of alte native, locally targeted
strategies, such as g m therapy, amtisense otigmtucleotides,
pholodynamic therapy and recombinant fusion proteins .
We apsssfuay ackeowtsdge the coambutimu of Guy Ledere. J. Geowey
rtakesins. saemni Takeshlla. Censlephar Passers . Takayuht Mature.
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